In vivo anti- and pro-tumour activities of the TLR2 ligand FSL-1

Immunobiology

Volumn 216, Issue 8, 2011, Pages 891-900

  Kiura, Kazuto ^a   Hasebe, Akira ^a   Saeki, Ayumi ^a   Segawa, Taku ^a   Okada, Futoshi ^b   Shamsul, Haque Mohammad ^a   Ohtani, Makoto ^a   Into, Takeshi ^c   Inoue, Nobuo ^a   Wakita, Minoru ^a   Shibata, Ken ichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c ASAHI UNIVERSITY   (Japan)

Author keywords

Antibody dependent cell mediated cytotoxicity; Cytotoxic T lymphocyte; FSL 1; Regulatory T cells; Toll like receptor 2; Tumour immunity

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; FIBROBLAST STIMULATING LIPOPEPTIDE 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FIBROSARCOMA; IMMUNIZATION; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; CD4 LYMPHOCYTE COUNT; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; FIBROSARCOMA; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOKINES; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 2;

EID: 79959499736     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.02.006     Document Type: Article

References (41)

1. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., Pulendran B. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 2003, 171:4984.
2. Akazawa T., Masuda H., Saeki Y., Matsumoto M., Takeda K., Tsujimura K., Kuzushima K., Takahashi T., Azuma I., Akira S., Toyoshima K., Seya T. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res. 2004, 64:757.
3. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L., Waldschmidt M., Weiner G.J. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 2001, 167:4878.
4. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007, 8:345.
5. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860.
6. Davila E., Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 2000, 165:539.
7. Davila E., Kennedy R., Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003, 63:3281.
8. Dillon S., Agrawal A., Van Dyke T., Landreth G., McCauley L., Koh A., Maliszewski C., Akira S., Pulendran B. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J. Immunol. 2004, 172:4733.
9. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137.
10. Harmey J.H., Bucana C.D., Lu W., Byrne A.M., McDonnell S., Lynch C., Bouchier-Hayes D., Dong Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int. J Cancer 2002, 101:415.
11. Huang B., Zhao J., Shen S., Li H., He K.L., Shen G.X., Mayer L., Unkeless J., Li D., Yuan Y., Zhang G.M., Xiong H., Feng Z.H. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007, 67:4346.
12. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121.
13. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987.
14. Jahrsdorfer B., Wooldridge J.E., Blackwell S.E., Taylor C.M., Griffith T.S., Link B.K., Weiner G.J. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc. Biol. 2005, 77:378.
15. Kiura K., Kataoka H., Yasuda M., Inoue N., Shibata K. The diacylated lipopeptide FSL-1 induces TLR2-mediated Th2 responses. FEMS Immunol. Med. Microbiol. 2006, 48:44.
16. Kochenderfer J.N., Chien C.D., Simpson J.L., Gress R.E. Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin. Immunol. 2007, 124:119.
17. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5:471.
18. Krieg A.M. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 2007, 117:1184.
19. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., Chang A., Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 2007, 178:6730.
20. Liu H., Komai-Koma M., Xu D., Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7048.
21. Luo J.L., Maeda S., Hsu L.C., Yagita H., Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297.
22. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 2002, 168:1212.
23. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., Paulos C.M., Palmer D.C., Touloukian C.E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C.S., Kerstann K.W., Feigenbaum L., Chan C.C., Restifo N.P. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362.
24. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato M., Ohta A. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 1999, 190:617.
25. Okada F., Hosokawa M., Hamada J.I., Hasegawa J., Kato M., Mizutani M., Ren J., Takeichi N., Kobayashi H. Malignant progression of a mouse fibrosarcoma by host cells reactive to a foreign body (gelatin sponge). Br. J. Cancer 1992, 66:635.
26. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59:3128.
27. Pidgeon G.P., Harmey J.H., Kay E., Da Costa M., Redmond H.P., Bouchier-Hayes D.J. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br. J. Cancer 1999, 81:1311.
28. Redecke V., Hacker H., Datta S.K., Fermin A., Pitha P.M., Broide D.H., Raz E. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol. 2004, 172:2739.
29. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001, 182:18.
30. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2001, 2:947.
31. Sfondrini L., Rossini A., Besusso D., Merlo A., Tagliabue E., Menard S., Balsari A. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 2006, 176:6624.
32. Shen Y., Fujimoto S. A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice. Cancer Res. 1996, 56:5005.
33. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2002, 2:389.
34. Shibata K., Hasebe A., Into T., Yamada M., Watanabe T. The N-terminal lipopeptide of a 44-kDa membrane-bound lipoprotein of Mycoplasma salivarium is responsible for the expression of intercellular adhesion molecule-1 on the cell surface of normal human gingival fibroblasts. J. Immunol. 2000, 165:6538.
35. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163:5211.
36. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115:739.
37. Stockfleth E., Trefzer U., Garcia-Bartels C., Wegner T., Schmook T., Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br. J. Dermatol. 2003, 149(Suppl. 66):53.
38. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., Joosten L.A., Akira S., Netea M.G., Adema G.J. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 2006, 116:485.
39. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21:335.
40. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 2004, 200:771.
41. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295.